Pharmacology of angiotensin receptors and AT1 receptor blockers

Basic Research in Cardiology

Volumn 93, Issue 2 SUPPL., 1998, Pages 15-23

  Chung, O ^a   Unger, T ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; BRADYKININ; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; LOSARTAN; RECEPTOR SUBTYPE; VALSARTAN;

ARTICLE; PHARMACOLOGY; RECEPTOR BINDING;

ANIMALS; BIPHENYL COMPOUNDS; HUMANS; PRODRUGS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031768054     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Anderson GH Jr, Streeten DHP, Dalakas TG (1977) Pressor responses to 1-Sar-8- Ala-Ang II (saralasin) in hypertensive subjects. Circ Res 40: 243-250 (Pubitemid 8058543)
2. Bottari SP, Taylor V, King IN, Bogdal S, deGasparo M (1991) Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins. Eur J Pharmacol 207: 157-163
3. Bottari SP, King IN, Reichlin S, Dahlstroem I, Lydon N, deGasparo M (1992) The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate. Biochem Biophys Res Commun 183 (1): 206-211
4. Boucher R, Asselin JH, Genest J (1994) A new enzyme leading to direct formation of angiotensin II. Circ Res 34 (Suppl 1): 1203-1209
5. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC (1991) Effects of nonpeptide Ang II receptor antagonist DuP 753 on blood ressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 4 (Part 2): 327S- 333S
6. Brechler V, Reichlin S, deGasparo M, Bottari SP (1994) Angiotensin II stimulates protein tyrosine phasphatase activity through a G-protein independent mechanism. Receptors and Channels 2: 89-97 (Pubitemid 2131736)
7. Buisson B, Bottari SP, deGasparo M, Gallo PN, Payet MD (1992) The angiotensin II AT2 receptor modulates T-type calcium current in non-differentiated NG 108-15 cells. FEBS Lett 309: 161-164
8. Burnier M, Rutschmann B, Nussberger J et al. (1993) Salt-dependent renal effects of an Ang II antagonist in healthy subjects. Hypertension 22: 339-347 (Pubitemid 23254082)
9. Case DB, Wallace JM, Larach JH (1979) Comparison between saralasin and converting enzyme inhibitor in hypertensive desease. Kidney Int 15: S107-S114
10. Cazaubon C, Gougat J, Guiraudou P, Broussier D, Lacour C, Rocon A, Galindo G, Barthelemy G, Gautret B, Nisato D (1992) In vitro and in vivo pharmacology of SR47436, an Ang II receptor antagonist. Am J Hypertens 5 (Part 2): 19A-20A
11. Chiu AT, Dunscomb JH, McCall DE, Benfield P, Baubonis W, Sauer B (1993) Characterization of angiotensin AT1a receptor isoform by its ligand binding signature. Regul Pept 44: 141-147
12. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists VII. Cellular and biochemical pharmacology of DuP 753, on orally active antihypertensive agent. J Pharmacol Exp Ther 252: 711-718 (Pubitemid 20101888)
13. Christ DD (1995) Human plasma protein binding of the Ang II receptor antagonist losartan potassium (DuP753/MK954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 35: 515-520
14. Criscione L, Bradley WA, Bühlmayer P et al. (1995) Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 13: 230- 250 (Pubitemid 26110791)
15. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M (1995) Valsartan, Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13: 230-250 (Pubitemid 26110791)
16. Criscione L, de Gasparo M, Buchlmayer P, Whitebread S, Ramjoue HP, Wood JM (1993) Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the Ang II AT1-receptor subtype. Br J Pharmacol 110: 761-771 (Pubitemid 23279290)
17. Darnell JE, Kerr IM, Stark GR (1994) Jak- STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (5164): 1415-1421 (Pubitemid 24217131)
18. De Gasparo M, Whitebread S (1995) Binding of valsartan to mammalian AT1- receptors. Regul Pept 59: 303-311
19. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR (1995) Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14-21
20. Dzau VJ, Gibbons GH, Pratt RE (1991) Molecular mechanisms of vascular reninangiotensin- system in myointimal hyperplasia. Hypertension 18 (suppl. 2): 100- 105
21. Dzau VJ, Gonzalez D, Kaempfer C, Dubin D, Wintroub BU (1987) Human neutrophils release serine proteases capable of activating prorenin. Circ Res 60: 595-601
22. Dzau VJ, Sasamura H, Hein L (1993) Heterogeneity of angiotensin synthetic pathways and receptor subtypes; physiological and pharmacological implications. J Hypertens 11 (Suppl 3): S13-S18 (Pubitemid 23120555)
23. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, Keenan RM, Ruffolo RR Jr, Weinstock J (1992) Pharmacological characterization of the nonpeptide Ang II receptor antagonist, SK & F108566. J Pharmacol Exp Ther 260: 175-181
24. Furakawa Y, Kishimoto S, Nishikawa K (1982) Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. Patents issued to Takeda Chemical Industries Ltd. on July 20, 1982, and October 19, 1982, respectively, U.S. Patents 4,340,598 and 4,355,040. Osaka, Japan
25. Garrison JC, Johnson DE, Campanile CP (1988) Evidence for the role of phosphorylase kinase, protein kinase C and other Ca2+ sensitive protein kinases in the response of hepatocytes to angiotensin II and vasopressin. J Biol Chem 259: 3283- 3292 (Pubitemid 14159456)
26. Goa KL, Wagstaff AJ (1996) Losartan Potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51: 820-84510
27. Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T (1996) Cardiac and vascular effects of long-term Losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 28: 397-402 (Pubitemid 26296041)
28. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger Th (1995) Chronic angiotensin AT1 receptor blockade improves cardiac function and metabolism in SHRSP. Hypertension 25 (3): 27 (abstr.)
29. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE (1991) Expression of AT2 receptors in the developing rat fetus. J Clin Invest 88 (3): 921-933
30. Hübner R, Högemann AM, Sunzel M, Riddel JG (1997) Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11 (Supp 2): S19-S25 (Pubitemid 27464501)
31. Kakar SS, Riel KK, Neill JD (1992) Differential expression of angiotensin II receptor subtype mRNAs (AT-1A and AT-1B) in the rat brain. Biochem Biophys Res Commun 185 (2): 688-692
32. Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD (1992) Angiotensin II type-1 receptor subtype cDNAs: Differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 183: 1090-1096
33. Kambayashi Y, Bardhan S, Tahahashi K et al. (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268 (33): 24543-24546 (Pubitemid 23335457)
34. Kang J, Posner P, Sumners C (1994) Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein. Am J Physio 267: C1289-C1397
35. Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y (1988) Angiotensin II induced expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 150: 52-59 (Pubitemid 18036203)
36. Kitami Y, Okura T, Marumoto K, Wakamiya R, Hiwada K (1992) Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Commun 188 (1): 446-452
37. Lafayette RA, Mayer G, Park SK, Meyer TW (1992) Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766-771
38. Linz W, Wiemer G, Gohlke P, Unger Th, Schölkens BA (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25-49
39. Lo MW, Goldberg MR, McCrea JB et al. (1995) Pharmacokinetics of losartan, an Ang II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58: 641-649 (Pubitemid 26018849)
40. Marino MR, Langenbacher KM, Ford NF, Uderman HD (1997) Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects. (abstract) Scientific meeting of the American Society of Hypertension 1997
41. Marrero MB, Schieffer B, Paxton WG et al. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375: 247-250
42. Martinez F, Schmitt F, Savoiu C, Leenhardt AF, Braoard R, Peronnet P, Lacour B, Grünfeld JP (1994) Effect of SR 47436 (BMS-186295) on renal hemodynamics and on glomerular permselectivity in health humans. J Am Soc Nephrol 5: 607
43. Meffert S, Stoll M, Unger Th (1995) The AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells in the presence of EGF and NGF. Naunyn- Schmiedeberg's Arch of Pharmacol 351 (suppl.): abstr. 471
44. Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger Th (1992) Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett 2: 150-152
45. Morimoto S, Ogihara T (1994) TCV-116: a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev 12: 153-164
46. Mukoyama M, Nakajama M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seventransmembrane receptors. J Biol Chem 268 (33): 24539-24542 (Pubitemid 23335456)
47. Müller P, Cohen T, deGasparo M, Sioufi A, Racinepoon A, Howald H (1994) Ang II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 47: 231-245 (Pubitemid 24330665)
48. Nakashima M, Uematsu T, Kosuge K (1992) Pilot study of the uricosuric effect of DuP-753, a new Ang II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333-335
49. Nakayima M, Horiuchi M, Morishita R, Yamada T, Pratt RE, Dzau VJ (1994) Growth inhibitory function of type 2 angiotensin II receptor: Gain of function study by in vivo gene transfer. Hypertension 24 (3): 37
50. Nisato D, Cazaubon C, Lacour C, Gougat J, Guiraudou P, Bernhart C, Perreaut P, Breliere JC, LeFur G (1992) Pharmacological properties of SR 47436, a non-peptidic Ang II receptor antagonist. Br J Pharmacol 105: 84P
51. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T et al. (1993) Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 46: 311-18 (Pubitemid 23218618)
52. Obermüller N, Unger Th, Culman J, Gohlke P, Bottari SP (1991) Distribution of angiotensin II receptor subtypes in rat brain nuclei. Neurosci Lett 132: 11-15
53. Ohtawa M, Takayama F, Saitoh K (1993) Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide Ang II receptor antagonist, in humans. Br J Clin Pharmacol 35: 290-297 (Pubitemid 23074055)
54. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K et al. (1997) Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 319: 137-146 (Pubitemid 27051327)
55. Pals DT, Mascucci FD, Denning GS, Sipos F, Fessler DC (1971) Role of the pressor action of Ang II in experimental hypertension. Circ Res 29: 673-681
56. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G (1996) Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 4: 19-25 (Pubitemid 26022405)
57. Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A (1994) Effects of the angiotensin II antagonist SR 47436 (BMS- 186295) on the pressor response to exogenous angiotensin II and the reninangiotensin system in sodium replete normal subjects. J Hypertens 12: 131
58. Sandberg K, Ji H, Clark AJL, Shapira H, Catt KJ (1992) Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 267 (14): 9455-9458
59. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H (1994) Comparative effects of chronic angiotensin- converting enzyme inhibition and AngII type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89: 2273-2282 (Pubitemid 24142808)
60. Shibouta Y, Inada Y, Ojima et al. (1993) Pharmacological profile of a highly potently and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-((2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl)-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1- (cyelohexyloxycarbonyloxy(- ethyl 2-ethoxy-1-((2'(1H-tetrazol-5- yl)biphenyl-4-yl)methyl)-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 266 (1): 114-120
61. Sica DA, Lo MW, Shaw WC et al. (1995) The pharmacokinetics of losartan in renal insufficiency. J Hypertens 13 (Suppl 1): S49-S52
62. Siegl PKS (1993) Discovery of losartan, the first specific non-peptide Ang II receptor antagonist. J Hypertens 11 (Suppl 3): S19-S22 (Pubitemid 23120556)
63. Smith MC, Barrows S, Meibohm A et al. (1995) The effects of Ang II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens 8: 1177-1183
64. Stauss HM, Zhu Y, Redlich T, Adamiak D, Mott A, Persson PB, Unger Th (1994) Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk 1: 255-262
65. Stoll M, Steckelings UM, Bottari SP, Unger Th (1993) Regulation of endothelial growth: role of the angiotensin II AT2- receptor. Circulation 88 (suppl.4, part 2): I-469 (abstr.)
66. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger Th (1995) The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651-657
67. Stouffer GA, Owens GK (1992) Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor b1. Circ Res 70: 820-828
68. Strohmenger HU, Lindner KH, Wienen W, Vogt J (1997) Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs Resuscitation 35 (1): 61-8 (Pubitemid 27312106)
69. Timmermans PB, Chiu AT, Herblin WF, Wong PC, Smith RD (1992) Angiotensin II receptor subtypes. Am J Hypertens (suppl 6, pt1): 406-410
70. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 32: 135-165
71. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD (1993) Ang II receptors and Ang II receptor antagonists. Pharmacol Rev 45: 205-251
72. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF (1991) Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12: 55-61
73. Tsutsumi K, Saavedra JM (1991) Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Amer J Physiol 261: R209-R216
74. Unger Th, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu YZ (1996) Angiotensin receptors. J Hypertens 14 (suppl 5): S95-103
75. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A(1990) Ang II-forming pathways in normal and failing human hearts. Circ Res 66: 883-890 (Pubitemid 20126420)
76. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A (1990) identification of a highly specific chymase as the major angiotensin-II-forming enzyme in the human heart. J Biol Chem 265: 22348- 22357 (Pubitemid 120014308)
77. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA, Franz RG, Gaitanopoulos DE, Girard GR, Gleason JG, Hill DT, Morgan TM, Peishoff CE, Aiyar N, Brooks DP, Fredrickson TA, Ohlstein EH, Ruffolo RR Jr, Stack EJ, Sulpizio AC, Weidley EF, Edwards RM (1991) 1- (Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 34: 1514-1517
78. Wintroub BU, Klickstein LB, Watt KW (1981) Ahuman neutrophil dependent pathway for generation of Ang II. J Clin Invest 68: 484-490
79. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP753 - an orally active antihypertensive agent. J Pharmacol Exp Ther 255: 211-217 (Pubitemid 20361505)
80. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide Ang II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 726-732 (Pubitemid 20101890)